A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

The big hey­day of mar­ket delir­i­um re­lat­ed to any­thing pos­i­tive in new Covid-re­lat­ed da­ta has pe­tered out as Omi­cron pass­es over, but lit­tle Eiger Bio­Phar­ma­ceu­ti­cals did get a quick pop-up in the stock price $EIGR this morn­ing af­ter re­port­ing some up­beat re­sults from its Phase III study of pe­gy­lat­ed in­ter­fer­on lamb­da.

Eiger says it’s beat­ing a path to the FDA to see about a snap emer­gency use au­tho­riza­tion for its treat­ment af­ter gath­er­ing late-stage da­ta from close to 2,000 pa­tients — 84% of whom had at least one vac­ci­na­tion against Covid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER